340B HIV/AIDS clinics say drugmaker Gilead's forthcoming cut in pharmacy reimbursement for the company's medicines that uninsured individuals get for free could rock their finances to the core. | Shutterstock

Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say

Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS clinics say the change could rock their finances to the core, and they are pushing back hard against it.

Gilead said in an April 8 statement that “dispensing pharmacies will be reimbursed for the amount paid for each bottle plus a dispensing fee and an administrative fee.” The company said the change “will help strengthen the program model so we can help eligible people living with and at risk for HIV access their free Gilead medication for years to come, while also continuing to drive innovation that expands options for HIV treatment and prevention.”

Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS clinics say the change could rock their finances to the core, and they are pushing back hard against it.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer